Skip to main content

Table 6 MMRM and LOCF_ANCOVA analyses of VAS overall pain severity in Studies 1 and 2.

From: The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

  

STUDY 1

STUDY 2

MMRM

THERAPY

Week

N

Mean change

Std.error

p-value

N

Mean change

Std.error

p-value

DULOX

1

120

-2.69

1.97

.181

121

-2.02

1.89

.157

PLACEBO

1

113

1.04

2.04

 

134

1.38

1.79

 

DULOX

2

113

-8.20

1.87

.003

108

-6.95

2.04

.003

PLACEBO

2

108

-0.42

1.93

 

127

0.91

1.90

 

DULOX

3

105

-10.46

1.95

.005

106

-9.81

1.90

< .001

PLACEBO

3

101

-2.56

2.01

 

119

-1.59

1.78

 

DULOX

5

99

-8.68

2.20

.028

95

-9.70

2.05

.011

PLACEBO

5

99

-1.85

2.24

 

108

-2.92

1.92

 

DULOX

7

91

-10.25

2.34

.016

87

-8.91

2.12

.254

PLACEBO

7

92

-2.26

2.38

 

94

-5.76

2.01

 

DULOX

9

83

-8.68

2.18

.055

80

-10.05

2.24

.135

PLACEBO

9

88

-2.80

2.20

 

88

-5.65

2.12

 

LOCF_ANCOVA

DULOX

LOCF_ANCOVA

121

-8.31

2.09

.019

121

-10.39

2.05

.037

PLACEBO

LOCF_ANCOVA

114

-1.40

2.18

 

134

-5.22

1.94

Â